Get startedLog in
    Picture of Pfizer logo

    PFE — Pfizer News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareConservativeLarge CapSuper Stock
    All News

    Brief: Pfizer Says Lorbrena Shows 55% Likelihood Of Progression-Free Survival At 7 Years In NSCLC Trial

    Picture of Pfizer logoPfizer
    29/05/2026 13:11
    BRIEF-Pfizer Says Lorbrena Shows 55% Likelihood Of Progression-Free Survival At 7 Years In NSCLC Trial
    May 29 (Reuters) - Pfizer Inc PFE.N:
    • ANNOUNCES SEVEN-YEAR RESULTS FROM CROWN TRIAL OF LORBRENA IN ADVANCED NSCLC
    • LORBRENA SHOWS 55% LIKELIHOOD OF PROGRESSION-FREE SURVIVAL AT 7 YEARS IN NSCLC TRIAL
    • LORBRENA MEDIAN PROGRESSION-FREE SURVIVAL NOT REACHED AT 7-YEAR FOLLOW-UP
    Source text: ID:nBwcgmnK2a
    Further company coverage: PFE.N

     ((Reutersbriefs@thomsonreuters.com;))

    Recent news on Pfizer

    See all news